Last reviewed · How we verify

Tadalafil 5mg

Aswan University · FDA-approved active Small molecule Quality 5/100

Tadalafil 5mg is a Small molecule drug developed by Aswan University. It is currently FDA-approved. Also known as: Cialis, phosphodiesterase type 5 (PDE5) inhibitor, Tadalafil, group B.

Tadalafil 5mg, marketed by Aswan University, is a well-established treatment in the erectile dysfunction market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in competition following patent expiry.

At a glance

Generic nameTadalafil 5mg
Also known asCialis, phosphodiesterase type 5 (PDE5) inhibitor, Tadalafil, group B, Tadilecto 5 mg
SponsorAswan University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tadalafil 5mg

What is Tadalafil 5mg?

Tadalafil 5mg is a Small molecule drug developed by Aswan University.

Who makes Tadalafil 5mg?

Tadalafil 5mg is developed and marketed by Aswan University (see full Aswan University pipeline at /company/aswan-university).

Is Tadalafil 5mg also known as anything else?

Tadalafil 5mg is also known as Cialis, phosphodiesterase type 5 (PDE5) inhibitor, Tadalafil, group B, Tadilecto 5 mg.

What development phase is Tadalafil 5mg in?

Tadalafil 5mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing